{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:34:13Z","timestamp":1789050853942,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16560-x","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:03:38Z","timestamp":1756292618000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tenofovir attenuates cytokine storm and bronchiolar damage in a mouse model of bleomycin-induced acute lung injury"],"prefix":"10.1038","volume":"15","author":[{"given":"Ic\u00edar P.","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Alfaro-Arnedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Canalejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-0952","authenticated-orcid":false,"given":"Jos\u00e9 G.","family":"Pichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-0150","authenticated-orcid":false,"given":"Jos\u00e9-Ram\u00f3n","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"P\u00e9rez-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"16560_CR1","doi-asserted-by":"publisher","first-page":"e1004086","DOI":"10.1371\/journal.pmed.1004086","volume":"20","author":"L Turtle","year":"2023","unstructured":"Turtle, L. et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 20, e1004086. https:\/\/doi.org\/10.1371\/journal.pmed.1004086 (2023).","journal-title":"PLoS Med."},{"key":"16560_CR2","doi-asserted-by":"publisher","first-page":"e26573","DOI":"10.1097\/MD.0000000000026573","volume":"100","author":"Y Dong","year":"2021","unstructured":"Dong, Y. et al. HIV infection and risk of COVID-19 mortality: A meta-analysis. Med. (Baltim). 100, e26573. https:\/\/doi.org\/10.1097\/MD.0000000000026573 (2021).","journal-title":"Med. (Baltim)."},{"key":"16560_CR3","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1086\/386340","volume":"38","author":"XP Chen","year":"2004","unstructured":"Chen, X. P. & Cao, Y. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin. Infect. Dis. 38, 1030\u20131032. https:\/\/doi.org\/10.1086\/386340 (2004).","journal-title":"Clin. Infect. Dis."},{"key":"16560_CR4","unstructured":"European AIDS Clinical Society (EACS). Guidelines version 11.1, October 2022. Available at: https:\/\/www.eacsociety.org\/media\/guidelines-11.1_final_09-10.pdf"},{"key":"16560_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/QAI.0000000000000857","volume":"71","author":"MM Solomon","year":"2016","unstructured":"Solomon, M. M. et al. The safety of Tenofovir-Emtricitabine for HIV Pre-Exposure prophylaxis (PrEP) in individuals with active hepatitis B. J. Acquir. Immune Defic. Syndr. 71, 281\u2013286. https:\/\/doi.org\/10.1097\/QAI.0000000000000857 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"16560_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu, B., Huang, S. & Yin, L. The cytokine storm and COVID-19. J. Med. Virol. 93, 250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232 (2021).","journal-title":"J. Med. Virol."},{"key":"16560_CR7","doi-asserted-by":"publisher","first-page":"L379","DOI":"10.1152\/ajplung.00010.2008","volume":"295","author":"G Matute-Bello","year":"2008","unstructured":"Matute-Bello, G., Frevert, C. W. & Martin, T. R. Animal models of acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L379\u2013399. https:\/\/doi.org\/10.1152\/ajplung.00010.2008 (2008).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"16560_CR8","doi-asserted-by":"publisher","first-page":"101819","DOI":"10.1016\/j.isci.2020.101819","volume":"23","author":"N Bordag","year":"2020","unstructured":"Bordag, N. et al. Machine learning analysis of the bleomycin mouse model reveals the compartmental and Temporal inflammatory pulmonary fingerprint. iScience 23, 101819. https:\/\/doi.org\/10.1016\/j.isci.2020.101819 (2020).","journal-title":"iScience"},{"key":"16560_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172. https:\/\/doi.org\/10.1038\/s41590-018-0276-y (2019).","journal-title":"Nat. Immunol."},{"key":"16560_CR10","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao, M. et al. Single-cell landscape of Bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842\u2013844. https:\/\/doi.org\/10.1038\/s41591-020-0901-9 (2020).","journal-title":"Nat. Med."},{"key":"16560_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-020-0168-9","volume":"6","author":"W Wen","year":"2020","unstructured":"Wen, W. et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell. Discov. 6, 31. https:\/\/doi.org\/10.1038\/s41421-020-0168-9 (2020).","journal-title":"Cell. Discov"},{"key":"16560_CR12","doi-asserted-by":"publisher","first-page":"2156","DOI":"10.1038\/s41379-020-00661-1","volume":"33","author":"AC Borczuk","year":"2020","unstructured":"Borczuk, A. C. et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and new York City. Mod. Pathol. 33, 2156\u20132168. https:\/\/doi.org\/10.1038\/s41379-020-00661-1 (2020).","journal-title":"Mod. Pathol."},{"key":"16560_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","volume":"40","author":"A Moeller","year":"2008","unstructured":"Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell. Biol. 40, 362\u2013382. https:\/\/doi.org\/10.1016\/j.biocel.2007.08.011 (2008).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"16560_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1136\/gutjnl-2018-317725","volume":"69","author":"TY Zhang","year":"2020","unstructured":"Zhang, T. Y. et al. A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut 69, 343\u2013354. https:\/\/doi.org\/10.1136\/gutjnl-2018-317725 (2020).","journal-title":"Gut"},{"key":"16560_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/QAD.0000000000003789","volume":"38","author":"S Chawki","year":"2024","unstructured":"Chawki, S. et al. Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with Tenofovir disoproxil\/emtricitabine. AIDS 38, 455\u2013464. https:\/\/doi.org\/10.1097\/QAD.0000000000003789 (2024).","journal-title":"AIDS"},{"key":"16560_CR16","doi-asserted-by":"publisher","first-page":"e63432","DOI":"10.1371\/journal.pone.0063432","volume":"8","author":"C Egger","year":"2013","unstructured":"Egger, C. et al. Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS One. 8, e63432. https:\/\/doi.org\/10.1371\/journal.pone.0063432 (2013).","journal-title":"PLoS One"},{"key":"16560_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1165\/rcmb.2009-0210ST","volume":"44","author":"G Matute-Bello","year":"2011","unstructured":"Matute-Bello, G. et al. An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals. Am. J. Respir Cell. Mol. Biol. 44, 725\u2013738. https:\/\/doi.org\/10.1165\/rcmb.2009-0210ST (2011).","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"key":"16560_CR18","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1038\/s41598-017-04561-4","volume":"7","author":"S Pineiro-Hermida","year":"2017","unstructured":"Pineiro-Hermida, S. et al. IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model. Sci. Rep. 7, 4290. https:\/\/doi.org\/10.1038\/s41598-017-04561-4 (2017).","journal-title":"Sci. Rep."},{"key":"16560_CR19","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.coph.2006.03.001","volume":"6","author":"K Kuba","year":"2006","unstructured":"Kuba, K., Imai, Y. & Penninger, J. M. Angiotensin-converting enzyme 2 in lung diseases. Curr. Opin. Pharmacol. 6, 271\u2013276. https:\/\/doi.org\/10.1016\/j.coph.2006.03.001 (2006).","journal-title":"Curr. Opin. Pharmacol."},{"key":"16560_CR20","doi-asserted-by":"publisher","unstructured":"Nabhan, A. N. et al. Targeted alveolar regeneration with Frizzled-specific agonists. Cell 186, 2995\u20133012 e2915, (2023). https:\/\/doi.org\/10.1016\/j.cell.2023.05.022","DOI":"10.1016\/j.cell.2023.05.022"},{"key":"16560_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.7326\/M20-3689","volume":"173","author":"J Del Amo","year":"2020","unstructured":"Del Amo, J. et al. Incidence and severity of COVID-19 in HIV-Positive persons receiving antiretroviral therapy: A cohort study. Ann. Intern. Med. 173, 536\u2013541. https:\/\/doi.org\/10.7326\/M20-3689 (2020).","journal-title":"Ann. Intern. Med."},{"key":"16560_CR22","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/QAD.0000000000003372","volume":"36","author":"J Del Amo","year":"2022","unstructured":"Del Amo, J. et al. Tenofovir disoproxil fumarate\/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection. AIDS 36, 2171\u20132179. https:\/\/doi.org\/10.1097\/QAD.0000000000003372 (2022).","journal-title":"AIDS"},{"key":"16560_CR23","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cmi.2021.06.023","volume":"27","author":"J Berenguer","year":"2021","unstructured":"Berenguer, J. et al. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV research network cohort. Clin. Microbiol. Infect. 27, 1678\u20131684. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.023 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"16560_CR24","doi-asserted-by":"publisher","unstructured":"Western Cape Department of Health in collaboration with the National Institute for Communicable & Diseases, S. A. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis 73, e2005-e (2015). https:\/\/doi.org\/10.1093\/cid\/ciaa1198 (2021).","DOI":"10.1093\/cid\/ciaa1198"},{"key":"16560_CR25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/QAD.0000000000003314","volume":"36","author":"G Li","year":"2022","unstructured":"Li, G. et al. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 36, 1689\u20131696. https:\/\/doi.org\/10.1097\/QAD.0000000000003314 (2022).","journal-title":"AIDS"},{"key":"16560_CR26","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1093\/jac\/dkac177","volume":"77","author":"DK Nomah","year":"2022","unstructured":"Nomah, D. K. et al. Impact of Tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. J. Antimicrob. Chemother. 77, 2265\u20132273. https:\/\/doi.org\/10.1093\/jac\/dkac177 (2022).","journal-title":"J. Antimicrob. Chemother."},{"key":"16560_CR27","doi-asserted-by":"publisher","first-page":"ofaa455","DOI":"10.1093\/ofid\/ofaa455","volume":"7","author":"O Ayerdi","year":"2020","unstructured":"Ayerdi, O. et al. Preventive efficacy of tenofovir\/emtricitabine against severe acute respiratory syndrome coronavirus 2 among Pre-Exposure prophylaxis users. Open. Forum Infect. Dis. 7, ofaa455. https:\/\/doi.org\/10.1093\/ofid\/ofaa455 (2020).","journal-title":"Open. Forum Infect. Dis."},{"key":"16560_CR28","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1128\/AAC.45.12.3381-3386.2001","volume":"45","author":"Z Zidek","year":"2001","unstructured":"Zidek, Z., Frankova, D. & Holy, A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES, macrophage inflammatory protein 1alpha) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1beta) production. Antimicrob. Agents Chemother. 45, 3381\u20133386. https:\/\/doi.org\/10.1128\/AAC.45.12.3381-3386.2001 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"16560_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/s0014-2999(03)02110-1","volume":"475","author":"Z Zidek","year":"2003","unstructured":"Zidek, Z., Potmesil, P., Kmoniekova, E. & Holy, A. Immunobiological activity of N-[2-(phosphonomethoxy)alkyl] derivatives of N6-substituted adenines, and 2,6-diaminopurines. Eur. J. Pharmacol. 475, 149\u2013159. https:\/\/doi.org\/10.1016\/s0014-2999(03)02110-1 (2003).","journal-title":"Eur. J. Pharmacol."},{"key":"16560_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/QAI.0b013e3182185276","volume":"57","author":"J Melchjorsen","year":"2011","unstructured":"Melchjorsen, J. et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12\/IL-10 balance in human primary cells. J. Acquir. Immune Defic. Syndr. 57, 265\u2013275. https:\/\/doi.org\/10.1097\/QAI.0b013e3182185276 (2011).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"16560_CR31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12931-019-1102-2","volume":"20","author":"L Li","year":"2019","unstructured":"Li, L. et al. Tenofovir Alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-beta1\/Smad3 signaling pathway. Respir Res. 20, 163. https:\/\/doi.org\/10.1186\/s12931-019-1102-2 (2019).","journal-title":"Respir Res."},{"key":"16560_CR32","doi-asserted-by":"publisher","first-page":"e0261067","DOI":"10.1371\/journal.pone.0261067","volume":"16","author":"SW Lee","year":"2021","unstructured":"Lee, S. W. et al. Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K\/Akt\/mTOR signaling pathway. PLoS One. 16, e0261067. https:\/\/doi.org\/10.1371\/journal.pone.0261067 (2021).","journal-title":"PLoS One"},{"key":"16560_CR33","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","volume":"19","author":"M Chien","year":"2020","unstructured":"Chien, M. et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J. Proteome Res. 19, 4690\u20134697. https:\/\/doi.org\/10.1021\/acs.jproteome.0c00392 (2020).","journal-title":"J. Proteome Res."},{"key":"16560_CR34","doi-asserted-by":"publisher","first-page":"e00674","DOI":"10.1002\/prp2.674","volume":"8","author":"J Ju","year":"2020","unstructured":"Ju, J. et al. Nucleotide analogues as inhibitors of SARS-CoV polymerase. Pharmacol. Res. Perspect. 8, e00674. https:\/\/doi.org\/10.1002\/prp2.674 (2020).","journal-title":"Pharmacol. Res. Perspect."},{"key":"16560_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/QAD.0000000000001744","volume":"32","author":"AT Podany","year":"2018","unstructured":"Podany, A. T. et al. Plasma and intracellular pharmacokinetics of Tenofovir in patients switched from Tenofovir disoproxil fumarate to Tenofovir Alafenamide. AIDS 32, 761\u2013765. https:\/\/doi.org\/10.1097\/QAD.0000000000001744 (2018).","journal-title":"AIDS"},{"key":"16560_CR36","doi-asserted-by":"publisher","unstructured":"Park, S. J. et al. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. mBio 11,  e01114\u201320. https:\/\/doi.org\/10.1128\/mBio.01114-20 (2020)","DOI":"10.1128\/mBio.01114-20"},{"issue":"e1019","key":"16560_CR37","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an Interferon-Stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181 (e1019), 1016\u20131035. https:\/\/doi.org\/10.1016\/j.cell.2020.04.035 (2020).","journal-title":"Cell"},{"key":"16560_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116. https:\/\/doi.org\/10.1038\/nature03712 (2005).","journal-title":"Nature"},{"key":"16560_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.7555\/JBR.34.20200044","volume":"34","author":"Y Yun","year":"2020","unstructured":"Yun, Y. et al. Identification of therapeutic drugs against COVID-19 through computational investigation on drug repurposing and structural modification. J. Biomed. Res. 34, 458\u2013469. https:\/\/doi.org\/10.7555\/JBR.34.20200044 (2020).","journal-title":"J. Biomed. Res."},{"key":"16560_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1755-1536-7-8","volume":"7","author":"T Volckaert","year":"2014","unstructured":"Volckaert, T. & De Langhe, S. Lung epithelial stem cells and their niches: Fgf10 takes center stage. Fibrogenesis Tissue Repair. 7, 8. https:\/\/doi.org\/10.1186\/1755-1536-7-8 (2014).","journal-title":"Fibrogenesis Tissue Repair."},{"key":"16560_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fpubh.2020.00152","volume":"8","author":"JM Jin","year":"2020","unstructured":"Jin, J. M. et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front. Public. Health. 8, 152. https:\/\/doi.org\/10.3389\/fpubh.2020.00152 (2020).","journal-title":"Front. Public. Health"},{"key":"16560_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. 20, 442\u2013447. https:\/\/doi.org\/10.1038\/s41577-020-0348-8 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"16560_CR43","doi-asserted-by":"publisher","first-page":"116228","DOI":"10.1016\/j.taap.2022.116228","volume":"454","author":"R Lamichhane","year":"2022","unstructured":"Lamichhane, R., Patial, S. & Saini, Y. Higher susceptibility of males to bleomycin-induced pulmonary inflammation is associated with sex-specific transcriptomic differences in myeloid cells. Toxicol. Appl. Pharmacol. 454, 116228. https:\/\/doi.org\/10.1016\/j.taap.2022.116228 (2022).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"16560_CR44","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/S0002-9440(10)62470-4","volume":"166","author":"M Gharaee-Kermani","year":"2005","unstructured":"Gharaee-Kermani, M., Hatano, K., Nozaki, Y. & Phan, S. H. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 166, 1593\u20131606. https:\/\/doi.org\/10.1016\/S0002-9440(10)62470-4 (2005).","journal-title":"Am. J. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16560-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:03:41Z","timestamp":1756292621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16560-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16560"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16560-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"27 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr L P\u00e9rez-Mart\u00ednez has received compensation for lectures from Abbvie, Bristol-Myers Squibb, Gilead Sciences, and Janssen. Dr. JR Blanco has carried out consulting work for Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Moderna, Pfizer and ViiV Healthcare; has received compensation for lectures from Abbvie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, Pfizer and ViiV Healthcare, as well as grants and payments for the development of educational presentations for Gilead Sciences, Bristol-Myers Squibb and ViiV Healthcare. The rest of the authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31570"}}